Coated (e.g., Microcapsules) Patents (Class 424/490)
  • Patent number: 12290594
    Abstract: A bamboo charcoal powder-based false eyelash is obtained by evenly mixing 90-96% of polyester particles, 3-8% of bamboo charcoal powder and 1-2% of adjuvant, subsequently hot melting, wire drawing and forming and then cooling. The false eyelash can be subjected to not only chemical sharpening tip but also physical sharpening tip, has greatly reduced weight and is environmental-friendly; an organosilicon quaternary ammonium salt structure and three chlorine atoms in the adjuvant synergistically take antibacterial effects, and a long carbon chain further enhances an antibacterial effect.
    Type: Grant
    Filed: January 2, 2024
    Date of Patent: May 6, 2025
    Assignee: Qingdao Futesen Plastic Technology Co., Ltd
    Inventors: Kexiu Li, Zhaozhong Zhang
  • Patent number: 12280349
    Abstract: In various embodiments, the present invention is directed to a facile one-pot reverse emulsion process to assemble core-shell nanoparticles (CS-SMNPs) into bright and noniridescent photonic supraballs. In one or more embodiments, the present invention is directed to core-shell nanoparticles having an inner high refractive index (RI) core and an outer low RI shell. In one or more embodiment, the present invention includes core-shell nanoparticles using high RI (˜1.74) melanin cores and low-RI (˜1.45) silica shells. In various embodiments, these nanoparticles may be self-assembled into bright and noniridescent supraballs using a scalable one-pot reverse emulsion process. According to various embodiments of the present invention, it is possible to generate a full spectrum of structural colors with the combination of only two ingredients, synthetic melanin and silica.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: April 22, 2025
    Assignees: The University of Akron, University of California, San Diego
    Inventors: Ali Dhinojwala, Ming Xiao, Ziying Hu, Matthew Shawkey, Nathan Gianneschi
  • Patent number: 12284551
    Abstract: A multi-link device (MLD) configured for reporting per-port frame replication and elimination for reliability (FRER) capabilities uses a per-Port FRER-capabilities object generated by upper MLD MAC layer to indicate per-Port FRER capabilities of lower layers including lower MAC and PHY layers. The per-port FRER capabilities of the lower layers may be reported using the per-Port FRER-capabilities object to an upper layer such as an FRER layer. The per-Port FRER-capabilities object may indicate at least whether or not a port between the upper MLD MAC layer and the FRER layer supports frame replication and duplication elimination capabilities in the underlying MAC and PHY layers.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: April 22, 2025
    Assignee: Intel Corporation
    Inventors: Dave A. Cavalcanti, Juan Fang
  • Patent number: 12274793
    Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.
    Type: Grant
    Filed: October 10, 2024
    Date of Patent: April 15, 2025
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 12275791
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: April 15, 2025
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Daniel Fallon, Asya Grinberg, William Haney, Steven O'Neil, Nicolai Wagtmann, Ronnie Wei, Bradley M. Lunde, Bianka Prinz
  • Patent number: 12275885
    Abstract: A method includes mixing a dopant salt of at least one of cobalt, nickel, zinc, and scandium with a silicate, in a solvent, to form a first solution. The method includes mixing the first solution with a solvent mixture to form a second solution. The method further includes mixing the second solution with an acid to form an acid solution. The method further includes adding a catalyst and a polymer to the acid solution to form the doped PCM. The doped PCM includes the catalyst, the polymer, at least one of cobalt, nickel, zinc, and scandium, and SiO2.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: April 15, 2025
    Assignee: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS
    Inventors: Md. Hasan Zahir, Kashif Irshad, Amjad Ali, Ridha Ben Ali Ben Mansour, Hafiz Ali
  • Patent number: 12269001
    Abstract: Provided are: a flow channel structure with which lipid particles or micelles, which are useful as nano-sized carriers, for example, in drug delivery systems, are produced with good control of particle size; and a method for forming lipid particles or micelles using the same. Said flow channel structure has a two-dimensional structure such as one in which multiple structural elements (baffles) of a specified width are alternately disposed from the two side faces in a micro-sized flow channel through which feedstock solutions are flowed.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: April 8, 2025
    Assignee: National University Corporation Hokkaido University
    Inventors: Manabu Tokeshi, Masatoshi Maeki, Yusuke Sato, Hideyoshi Harashima
  • Patent number: 12268783
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: April 8, 2025
    Assignee: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 12269002
    Abstract: Disclosed are microcapsule compositions and their preparation methods. The microcapsule composition has a microcapsule dispersed in an aqueous phase. The microcapsule has a microcapsule core and a microcapsule wall encapsulating the microcapsule core. The microcapsule core contains an active material selected from the group consisting of a fragrance, cosmetic active, malodor counteractant, and combinations thereof. The microcapsule wall is formed of a polymeric network comprising of at least three moieties: (i) a first moiety derived from a chitosan, (ii) a second moiety derived from a polyisocyanate, and (iii) a third moiety derived from a polyphenol. Also disclosed are consumer products contain such a microcapsule composition.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: April 8, 2025
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Li Xu, Yabin Lei, Yi Zhang, Takashi Sasaki, Ronald Gabbard, Lewis Michael Popplewell
  • Patent number: 12263241
    Abstract: The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.
    Type: Grant
    Filed: May 14, 2024
    Date of Patent: April 1, 2025
    Assignee: J.D.I.P., LLC
    Inventors: Jesse Loughman, Tyler Hutchinson
  • Patent number: 12257348
    Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: May 23, 2021
    Date of Patent: March 25, 2025
    Assignee: Sol-Gel Technologies Ltd.
    Inventors: Ofer Toledano, Karine Neimann, Danil Finkel-Moiseev, Maya Erlich, Dorit Marco
  • Patent number: 12246010
    Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: March 11, 2025
    Assignee: Iterion Therapeutics, Inc.
    Inventors: Steven David Dykstra, Henry Havel, Stephen Horrigan, Roger Harrison, Jeffrey Larson, Jonathan Northrup, Theodore Laslo, Garry Gwozdz
  • Patent number: 12226404
    Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: February 18, 2025
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert O. Williams, III, Keith P. Johnston, Prapasri Sinswat, Jason T. McConville, Robert Talbert, Jay I. Peters, Alan B. Watts, True L. Rogers
  • Patent number: 12213953
    Abstract: This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, or a pharmaceutically acceptable salt thereof, that can be administered to a human subject in need thereof. The disclosure also provides pharmaceutical compositions for treatment of orthostatic hypotension that can be administered once or twice a day.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 4, 2025
    Assignee: XENAMED CORP.
    Inventors: Yogesh Dandiker, Maulik Kiritkumar Panchal, Xiao Yu
  • Patent number: 12194046
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: January 14, 2025
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 12179172
    Abstract: Provided are a superabsorbent polymer and a preparation method thereof. More particularly, provided are a superabsorbent polymer including a fine powder reassembly, wherein the superabsorbent polymer exhibits excellent absorption performances and absorption rate, and does not cause deterioration of physical properties such as water retention capacity (CRC) or absorbency under pressure (AUP), and a preparation method thereof.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: December 31, 2024
    Assignee: LG Chem, Ltd.
    Inventors: Yong Seok Choi, Yeon Woo Hong, Eunji Shin, Taebin Ahn
  • Patent number: 12178919
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
    Type: Grant
    Filed: August 1, 2024
    Date of Patent: December 31, 2024
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 12178917
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 31, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Patent number: 12161736
    Abstract: A hydrophilic inorganic powder having excellent self-dispersibility in water or an aqueous solvent, which could not be conventionally achieved, and a cosmetic preparation containing the hydrophilic inorganic powder are provided by combining a hydrophilic surfactant and lipophilic surfactant. There is provided the hydrophilic inorganic powder comprising an inorganic powder as a base material; a hydrophobic-coat that covers the surface of the inorganic powder; and a hydrophilic-coat that covers the hydrophobic-coat, wherein ingredients of the hydrophilic-coat comprises both a hydrophilic surfactant and a lipophilic surfactant, and each of the hydrophilic surfactant and the lipophilic surfactant has a branched alkyl moiety in their molecules, wherein the hydrophilic inorganic powder has self-dispersibility in water or an aqueous solvent.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: December 10, 2024
    Assignee: MIYOSHI KASEI, INC.
    Inventor: Yukio Hasegawa
  • Patent number: 12165778
    Abstract: Methods for forming particulates that are highly consistent with regard to shape, size, and content are described. Particulates are suitable for use as reference materials. Methods can incorporate actinides and/or lanthanides, e.g., uranium, and can be used for forming certified reference materials for use in the nuclear industry. Methods include formation of an aerosol from an oxalate salt solution, in-line diagnostics, and collection of particles of the aerosol either in a liquid impinger or on a solid surface.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 10, 2024
    Assignee: Battelle Savannah River Alliance, LLC
    Inventors: Matthew S. Wellons, Michael A. Devore, II, Wendy W. Kuhne
  • Patent number: 12163883
    Abstract: The present invention relates to sensors for detecting the presence or measuring the concentration of a target analyte, the sensor comprising: (i) a first phase comprising a first crosslinked polymer; (ii) a second phase comprising a second crosslinked polymer; and (ill) a target analyte recognition agent; the first phase and second phase arranged to form an optical grating. The first crosslinked polymer comprises low amounts of a crosslinking agent. The present invention also relates to methods of making a sensor for detecting the presence or measuring the concentration of a target analyte.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: December 10, 2024
    Assignee: Cambridge Enterprise Limited
    Inventors: Gita Khalili Moghaddam, Christopher Robin Lowe, Jeffrey Blyth
  • Patent number: 12156943
    Abstract: The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 3, 2024
    Assignee: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Patent number: 12156873
    Abstract: A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an ? adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating ? adrenergic receptor of the patient with an agonist of the receptor.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: December 3, 2024
    Assignee: ADS Therapeutics LLC
    Inventors: Scott Whitcup, Rong Yang, Jinsong Ni
  • Patent number: 12144897
    Abstract: A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: November 19, 2024
    Assignee: The Florida International University Board of Trustees
    Inventors: Madhavan Nair, Andrea Raymond, Arti Vashist
  • Patent number: 12144896
    Abstract: The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 19, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, UNIVERSITE D'ANGERS, CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS
    Inventors: Giovanna Lollo, Jean-Pierre Benoit, Marie Brachet-Botineau
  • Patent number: 12138362
    Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.
    Type: Grant
    Filed: November 15, 2023
    Date of Patent: November 12, 2024
    Assignee: MicroVention, Inc.
    Inventors: Gregory M. Cruise, Steve Plotkin, Xinping Wu
  • Patent number: 12134779
    Abstract: The present disclosure provides feeder hydrogel particles that can function to support the growth, proliferation, and/or activation of a target cell in culture. The present disclosure also provides methods of culturing target cells with feeder hydrogel particles.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: November 5, 2024
    Assignee: Slingshot Biosciences, Inc.
    Inventors: Anh Tuan Nguyen, Jeffrey Kim, Keunho Ahn, Daixuan Zhang
  • Patent number: 12121612
    Abstract: A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: October 22, 2024
    Assignee: Sigrid Therapeutics AB
    Inventors: Robert Csikasz, Tore Bengtsson, Natalia Kupferschmidt, Alfonso E. Garcia-Bennett
  • Patent number: 12090233
    Abstract: Masking particles which comprise a drug-containing particle containing a drug, an acid, and a carbonate, the drug-containing particle being coated with a coating layer containing a water-insoluble polymer sufficiently suppress drug release in the oral cavity and pharynx, rapidly release a drug after swallowing, and easily control the release suppression time of a drug. The acid may be at least one organic acid. The carbonate may be at least one water-soluble carbonate. Oral pharmaceutical compositions include tablets, granules, fine granules, powders.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: September 17, 2024
    Assignee: TOWA PHARMACEUTICAL CO., LTD.
    Inventors: Tatsuya Honjo, Megumi Murahashi, Masaki Sato, Kayo Yuminoki, Isamu Saeki, Yutaka Okuda
  • Patent number: 12083229
    Abstract: There is provided an ocular drug delivery formulation comprising a delivery carrier comprising a cellulosic polymer and an anionic polysaccharide and nanoparticles comprising an amphiphilic non-ionizable block copolymer and a cannabinoid. The formulation has a gel point of about 30° C. to about 37° C.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 10, 2024
    Assignee: INMED PHARMACEUTICALS INC.
    Inventors: Sazzad Hossain, Maryam Kabiri, Vikramaditya Ganapati Yadav
  • Patent number: 12077728
    Abstract: Laundry care additive particles and a dryer sheet that include a water soluble carrier and capsules characterized by substantially inorganic shells, for example silica-based shells. The present disclosure further relates to methods of making and using such compositions.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: September 3, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Andre Martim Barros, Mariana B. T. Cardoso, Johan Smets, Steven Daryl Smith, Pierre Daniel Verstraete, Valerie Wong
  • Patent number: 12064522
    Abstract: A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more silicon oxide materials is provided. The method entails alternating exposing the particles to gaseous or vaporous SiCl4 and gaseous or vaporous H2O at a reduced temperature and in the absence of a catalyst.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: August 20, 2024
    Assignee: Applied Materials, Inc.
    Inventors: Fei Wang, Miaojun Wang, Colin C. Neikirk, Jonathan Frankel, Pravin K. Narwankar
  • Patent number: 12060368
    Abstract: The present invention relates to a novel selenophenochromene hydroxamic acids as angiogenesis inhibitors, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment or prevention of various diseases and disorders by administration of such substances.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 13, 2024
    Assignee: Latvian Institute of Organic Synthesis
    Inventors: Pavels Arsenjans, Jelena Vasiljeva, Ilona Domraceva
  • Patent number: 12052988
    Abstract: Provided is an antibacterial liquid with excellent temporal stability in which caking due to sedimentation of solid components does not occur and with which a film capable of stably maintaining antibacterial properties can be formed, in a case of being formed into a film. Also provided are an antibacterial film formed using the antibacterial liquid, and a spray and a cloth including the antibacterial liquid. The antibacterial liquid includes an antibacterial microparticle, a binder, and a solvent, in which the antibacterial microparticle contains a silver-supporting inorganic oxide, the binder includes at least one compound having a siloxane bond, the solvent includes an alcohol and water, the concentration of solid contents is less than 5% by mass with respect to the total mass of the antibacterial liquid, and the content of the compound having a siloxane bond is 60% by mass or more with respect to the total solid content of the antibacterial liquid.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: August 6, 2024
    Assignee: FUJIFILM Corporation
    Inventors: Naotoshi Sato, Mitsumasa Hamano
  • Patent number: 12042559
    Abstract: The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: July 23, 2024
    Inventors: Kanji Meghpara, Jaydeep Vagashiya, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit, Harpreet Kaur Sandhu, Siva Ram Kiran Vaka, Namdev B. Shelke, Ashish Chatterji
  • Patent number: 12029767
    Abstract: The present disclosure relates to a method for treating or preventing a viral and/or bacterial respiratory infection in a subject, the method comprising administering to the respiratory tract of the subject an effective amount of one or more bacteria from family Pasteurellaceae.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: July 9, 2024
    Assignee: Telethon Kids Institute
    Inventors: Caitlyn Granland, Lea-Ann Kirkham, Peter Richmond
  • Patent number: 12029709
    Abstract: The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: July 9, 2024
    Assignee: De Motu Cordis Pty Ltd
    Inventors: John Fraser, Sean Mark Dalziel, Teresa Iley, Jonathan Brazier, Patrick Joseph Lynch, John Fredatovich, Benjamin Barnaby Trout
  • Patent number: 12027245
    Abstract: The present disclosure provides a pharmaceutical composition for multi-stage release of psychoactive substances including cannabinoids. The pharmaceutical composition comprises two or more staged compositions having different release profiles or different release time such that the one or more active agents in each of the two or more staged compositions are released into the subject's blood stream at different time points.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: July 2, 2024
    Assignee: Green Sky Creations LLC
    Inventors: Simon Robinson, Brad Douglass
  • Patent number: 12016840
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: June 25, 2024
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Patent number: 12016850
    Abstract: The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: June 25, 2024
    Assignees: Chiesi Farmaceutici S.p.A., Università degli Studi di Milano
    Inventors: Marisa Pertile, Andrea Gazzaniga, Matteo Cerea, Micol Cirilli
  • Patent number: 12016833
    Abstract: Exemplary embodiments of the present invention relate to a combination formulation for treatment or enhancing the therapy of liver disease, and more particularly, to a combination formulation prepared by containing colchicine and metformin as main active ingredients. The composition according to exemplary embodiments of the present invention may be used as an effective therapeutic agent for liver disease capable of treating and preventing liver fibrosis, liver cirrhosis, liver cancer, or hepatitis by reducing the amount of fat accumulated in the liver tissues by a synergistic effect of colchicine and metformin and lowering glucose tolerance and insulin tolerance and further, may be used as an excellent drug capable of replacing ursodeoxycholic acid.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: June 25, 2024
    Inventors: Ju Ho Yoon, Wang Jo Cha, Sun Ah Ham
  • Patent number: 12011509
    Abstract: The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: June 18, 2024
    Inventors: Anshuman Jakhmola, Jahangir Tavakkoli, Kevin Rod
  • Patent number: 11998638
    Abstract: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: June 4, 2024
    Assignee: AQTIS I.P B.V.
    Inventors: Henderikus Super, Paul Willem Mijnen, Pieter Gerard Zijlstra, Dirk Wybe Grijpma
  • Patent number: 11999829
    Abstract: The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: June 4, 2024
    Assignee: ETH ZURICH
    Inventors: Jean-Christophe Leroux, Simon Matoori, Olha Voznyuk Wuerthinger
  • Patent number: 11969449
    Abstract: This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: April 30, 2024
    Assignee: PROBIOTICAL S.P.A.
    Inventor: Giovanni Mogna
  • Patent number: 11957764
    Abstract: The disclosure relates to a protein-type nanoparticle for multi-specific antibody delivery, a preparation method, and its application. The protein-type nanoparticle includes a polyester and a protein with a hydrophobic domain, and the hydrophobic domain of the protein is bound with the polyester through hydrophobic interactions. The protein is at least one of albumin, globulin and cell wall protein. The protein-type nanoparticle of the present disclosure has excellent stability and biocompatibility. The protein-type nanoparticle is used to prepare a multi-specific antibody delivery platform (?Fc-NP) by binding anti-IgG-Fc antibody or anti-IgG-Fc antibody fragment, which can stably, quickly and easily bind to multiple specific antibodies through antigen-antibody interaction and enhance the therapeutic effect of specific antibodies.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: April 16, 2024
    Assignee: SOUTH CHINA UNIVERSITY OF TECHNOLOGY
    Inventors: Jun Wang, Zhiting Cao, Song Shen, Qianni Ye, Xiaojiao Du, Xianzhu Yang, Youyong Yuan
  • Patent number: 11957046
    Abstract: An electroluminescent device includes a first electrode and a second electrode facing each other; an emission layer disposed between the first electrode and the second electrode and including a plurality of quantum dots and a first hole transporting material having a substituted or unsubstituted C4 to C20 alkyl group attached to a backbone structure; a hole transport layer disposed between the emission layer and the first electrode and including a second hole transporting material; and an electron transport layer disposed between the emission layer and the second electrode.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 9, 2024
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Moon Gyu Han, Dae Young Chung, Kwanghee Kim, Eun Joo Jang, Chan Su Kim, Kun Su Park, Won Sik Yoon
  • Patent number: 11926467
    Abstract: A non-aspirating dispenser containing a gel therein for delivery to a desired surface such as a medical article. More specifically, a gel that is dispensed in the form of droplets that are free of air or a gas therein and with reduced drift potential. The dispenser has a container having a flexible bag therein enclosing a thixotropic gel, and has a pressurized gas that is capable of exerting pressure on the bag and forcing the gel out of said bag in a steady stream upon pressing an actuator that is operatively connected to an ejection valve. The bag is free of propellants, and does not produce an aerosol. The gel is thixotropic and is utilized for keeping medical instruments moist in order to prevent soils present thereon from drying out, which can make reprocessing of medical instruments more difficult and less effective. The dispenser implemented at a point of use for transport or prior to delayed reprocessing in the reprocessing area.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: March 12, 2024
    Assignee: AMERICAN STERILIZER COMPANY
    Inventors: Nancy-Hope E. Kaiser, Daniel Rochette, Bradley A. Baan
  • Patent number: 11925693
    Abstract: Polymeric nanoparticles comprising a defined set of biologically active agents that provide for targeted stimulation of non-responsive T cells, e.g. T cells involved in cancer, are provided.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: March 12, 2024
    Inventors: Qian Yin, Yu Wong, Mark M. Davis
  • Patent number: 11918011
    Abstract: Described are compositions and methods relate to stable, high-payload, non-porous enzyme-containing coated granules with improved resistance to activity loss during steam pelleting.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: March 5, 2024
    Assignee: DANISCO US INC.
    Inventors: Samuel A. Maurer, Nathaniel T. Becker, Douglas A. Dale, Peyman Moslemy, Michael Reichman, Alan Martin Allgeier